Sales in Johnson & Johnson’s Abiomed business declined in the second quarter due to procedure volume pressures related to its Impella device.
Source: MedTech Dive
You may also like
Facing Funding Losses, States Call Out Big Businesses...
Vicarious Surgical board proposes dissolving the...
Judge tosses another No Surprises lawsuit against...
Doctor pay to drop in 2027 under proposed Medicare pay...
Elevance shuts down D.C. Medicaid business, eyes...
Providence names new chief supply chain officer
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.